Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma
ContributorsMellinghoff, Ingo K; van den Bent, Martin J; Blumenthal, Deborah T; Touat, Mehdi; Peters, Katherine B; Clarke, Jennifer; Mendez, Joe; Yust-Katz, Shlomit; Welsh, Liam; Mason, Warren P; Ducray, François; Umemura, Yoshie; Nabors, Burt; Holdhoff, Matthias; Hottinger, Andreas F; Arakawa, Yoshiki; Sepulveda, Juan M; Wick, Wolfgang; Soffietti, Riccardo; Perry, James R; Giglio, Pierre; de la Fuente, Macarena; Maher, Elizabeth A; Schoenfeld, Steven; Zhao, Dan; Pandya, Shuchi S; Steelman, Lori; Hassan, Islam; Wen, Patrick Y; Cloughesy, Timothy F; INDIGO Trial Investigators
CollaboratorsMigliorini, Denis
Published inNew England journal of medicine, vol. 389, no. 7, p. 589-601
Publication date2023-08-17
First online date2023-06-04
Abstract
Keywords
- Humans
- Antineoplastic Combined Chemotherapy Protocols / therapeutic use
- Disease Progression
- Double-Blind Method
- Glioma / drug therapy
- Glioma / genetics
- Isocitrate Dehydrogenase / genetics
- Neoplasm Recurrence, Local / drug therapy
- Pyridines / adverse effects
- Antineoplastic Agents / therapeutic use
- Enzyme Inhibitors / therapeutic use
Affiliation entities
Research groups
Citation (ISO format)
MELLINGHOFF, Ingo K et al. Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma. In: New England journal of medicine, 2023, vol. 389, n° 7, p. 589–601. doi: 10.1056/NEJMoa2304194
Main files (1)
Article (Published version)
Secondary files (5)
Identifiers
- PID : unige:173928
- DOI : 10.1056/NEJMoa2304194
- PMID : 37272516
Additional URL for this publicationhttps://www.nejm.org/doi/10.1056/NEJMoa2304194
Journal ISSN0028-4793